Supplemental announcement in relation to proposed change of auditors
Filed with HKEX · Stock code 512 · · 6 pages · English
Summary by 6ix AI
Grand Pharmaceutical Group Limited has issued a supplemental announcement regarding the proposed change of auditors, detailing the reasons and plans for this transition. The Board emphasizes that this change is timely and necessary to enhance audit efficiency and support future development needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Grand Pharmaceutical Group Limited on 6ix
Earlier from Grand Pharmaceutical
- Proposed change of auditors
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Interim report 2026
- Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report
- Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report
Later from Grand Pharmaceutical
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- Voluntary announcement: the international multi-center phase III clinical trial for the treatment of pterygium of the group's global innovative ophthalmic drug CBT-001 has reached its primary clinical endpoint
- (1) Proposed change of auditors; and (2) notice of special general meeting
- Notice of the special general meeting
- Notice of availability to Non-registered Shareholders and Reply Form
Follow Grand Pharmaceutical into a list and get an email when it puts out news.
Follow Grand Pharmaceutical